Factors associated with Efavirenz discontinuation in a large community-based sample of patients

References

• Arnsten , JH , Demas , PA , Grant , RW , Gourevitch , MN , Farzadegan , H , Howard , AA and Schoenbaum , EE . 2002 . Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users . Journal of General Internal Medicine , 17 (5) : 377 – 381 .
   PubMed Web of Science ®Google Scholar
• Blanch , J , Martinez , E , Rousaud , A , Blanco , JL , Garcia-Viejo , MA , Peri , JM , Mallolas , J , De Lazzari , E , De Pablo , J and Gatell , JM . 2001 . Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz . Journal of Acquired Immune Deficiency Syndrome , 27 (4) : 336 – 343 .
   PubMed Web of Science ®Google Scholar
• Carr , A , Hudson , J , Chuah , J , Mallal , S , Law , M , Hoy , J , Doong , N , French , M , Smith , D and Cooper , DA . 2001 . HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study . AIDS , 15 (14) : 1811 – 1822 .
   PubMed Web of Science ®Google Scholar
• Carrieri , P , Spire , B , Duran , S , Katlama , C , Peyramond , D , Francois , C , Chene , G , Lang , JM , Moatti , JP and Leport , C . 2003 . Health-related quality of life after 1 year of highly active antiretroviral therapy . Journal Acquired Immune Deficiciency Syndrome , 32 (1) : 38 – 47 .
   PubMed Web of Science ®Google Scholar
• Cederfjall , C , Langius-Eklof , A , Lidman , K and Wredling , R . 2001 . Gender differences in perceived health-related quality of life among patients with HIV infection . AIDS Patient Care and Sexually Transmitted Diseases , 15 (1) : 31 – 39 .
   PubMed Web of Science ®Google Scholar
• Currier , JS , Spino , C , Grimes , J , Wofsy , CB , Katzenstein , DA , Hughes , MD , Hammer , SM and Cotton , DJ . 2000 . Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team . Journal of Acquired Immune Deficiency Syndrome , 24 (4) : 316 – 324 .
   PubMed Web of Science ®Google Scholar
• Delfraissy J Prise en charge des personnes infectées par le VIH, Flammarion Paris 2002
   Google Scholar
• Duran , S , Spire , B , Raffi , F , Walter , V , Bouhour , D , Journot , V , Cailleton , V , Leport , C and Moatti , JP . 2001 . Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART . HIV Clinical Trials , 2 (1) : 38 – 45 .
   PubMedGoogle Scholar
• Dybul , M , Fauci , AS , Bartlett , JG , Kaplan , JE and Pau , AK . 2002 . Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV . MMWR Recomm Rep , 51 (RR-7) : 1 – 55 .
   PubMedGoogle Scholar
• Ewing , J . 1984 . Detecting alcoholism . Journal of American Medical Association , 14 (252) : 1905 – 1907 .
   Google Scholar
• Fuhrer , R and Rouillon , F . 1989 . La version française de l'échelle CES-D. Description and translation of the autoevaluation scale (in French) . Psychiatrie et Psychobiologie , 4 : 163 – 166 .
   Google Scholar
• Lang , JP , Halleguen , O , Picard , A , Lang , JM and Danion , JM . 2001 . Apropos of atypical melancholia with Sustiva (efavirenz) . Encephale , 27 (3) : 290 – 293 .
   PubMedGoogle Scholar
• Lochet , P , Peyriere , H , Lotthe , A , Mauboussin , JM , Delmas , B and Reynes , J . 2003 . Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz . HIV Medicine , 4 (1) : 62 – 66 .
   PubMedGoogle Scholar
• Martin-Carbonero , L , Nunez , M , Gonzalez-Lahoz , J and Soriano , V . 2003 . Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine . HIV Clinical Trials , 4 (2) : 115 – 120 .
   PubMed Web of Science ®Google Scholar
• Murphy , DA , Greenwell , L and Hoffman , D . 2002 . Factors associated with antiretroviral adherence among HIV-infected women with children . Women Health , 36 (1) : 97 – 111 .
   PubMed Web of Science ®Google Scholar
• Negredo , E , Cruz , L , Paredes , R , Ruiz , L , Fumaz , CR , Bonjoch , A , Gel , S , Tuldra , A , Balague , M , Johnston , S , Arno , A , Jou , A , Tural , C , Sirera , G , Romeu , J and Clotet , B . 2002 . Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression . Clinical Infectious Diseases , 34 (4) : 504 – 510 .
   PubMed Web of Science ®Google Scholar
• Nieuwkerk , PT , Gisolf , EH , Reijers , MH , Lange , JM , Danner , SA and Sprangers , MA . 2001 . Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection . AIDS , 15 (15) : 1985 – 1991 .
   PubMed Web of Science ®Google Scholar
• Producer-information 1998 Efavirenz Sustiva, Dupont Pharmaceuticals Willington DE
   Google Scholar
• Saves , M , Raffi , F , Capeau , J , Rozenbaum , W , Ragnaud , JM , Perronne , C , Basdevant , A , Leport , C and Chene , G . 2002 . Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy . Clinical Infectious Diseases , 34 (10) : 1396 – 1405 .
   PubMed Web of Science ®Google Scholar
• Wilson , KA , Dowling , AJ , Abdolell , M and Tannock , IF . 2000 . Perception of quality of life by patients, partners and treating physicians . Quality of Life Research , 9 (9) : 1041 – 1052 .
   PubMed Web of Science ®Google Scholar